Astellas starts a second pivotal degrader trial
The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
Arvinas seeks to outdo Astellas
Early data are coming with the KRAS G12D degrader ARV-806.
ASCO-GU – J&J looks to a pasritamig combo
New data with pasritamig plus docetaxel support a recent pivotal start.
ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
Vir tempts Astellas
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
Astellas makes its KRAS degrader choice
The company discontinues one of its two KRAS G12D degraders.
